


Trimetazidine

Cat. No.:	HY-B0968A
CAS No.:	5011-34-7
Molecular Formula:	C ₁₄ H ₂₂ N ₂ O ₃
Molecular Weight:	266.34
Target:	Autophagy
Pathway:	Autophagy
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (469.32 mM)
* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.7546 mL	18.7730 mL	37.5460 mL
	5 mM	0.7509 mL	3.7546 mL	7.5092 mL
	10 mM	0.3755 mL	1.8773 mL	3.7546 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.81 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Trimetazidine is a selective long chain 3-ketoacyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor^{[1][2][3][4]}.

IC₅₀ & Target

IC₅₀: 75 nM (long chain 3-ketoacyl coenzyme A thiolase)^[2]
β-oxidation^[2]

	Autophagy ^[3] 3-hydroxyacyl-CoA dehydrogenase (HADHA) ^[4]
In Vitro	Trimetazidine (1-100 μ M; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induced by oxidation in a certain dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]
	Cell Line: Human umbilical vein endothelial cells (HUVECs)
	Concentration: 1 μ M, 10 μ M, 100 μ M
	Incubation Time: 24 hours
	Result: Enhanced the viability of the injured HUVECs induced by oxidation.
In Vivo	Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 and 20mg/kg doses significantly raises the seizure-threshold current in the ICES test in the mice ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
	Animal Model: Swiss albino male mice (24-35 g) ^[4]
	Dosage: 5 mg/kg, 10 mg/kg and 20 mg/kg; 10 mL/kg body weight
	Administration: Oral administration ; 1 hour
	Result: In 10 and 20mg/kg doses significantly raised the seizure-threshold current in the ICES test.

CUSTOMER VALIDATION

- Mol Cell. 2020 Oct 1;80(1):43-58.e7.
- Acta Pharmacol Sin. 2022 Feb 25.
- J Pharmaceut Biomed. 2020, 113870.
- Anatol J Cardiol. 2019 Nov;22(5):232-239.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Shenghu He, et al. Protective effects of trimetazidine against vascular endothelial cell injury induced by oxidation. Journal of Geriatric Cardiology, December 2008 , Vol 5 No 4.
- [2]. Kantor PF, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8.
- [3]. Jain S, et al. Trimetazidine exerts protection against increasing current electroshock seizure test in mice. Seizure. 2010 Jun;19(5):300-2.
- [4]. Chrusciel P, et al. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74(9):971-80.

[5]. Hossain F, et al. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. *Cancer Immunol Res.* 2015 Nov;3(11):1236-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA